N. Korea's under-5 mortality rate rises for 2nd year in 2023 during pandemic
North Korea's estimated mortality rate for children under age 5 reached 18 per 1,000 live births in 2023, marking two consecutive years of increase during the COVID-19 pandemic, United Nations data showed Tuesday.
The 2023 rate marks an increase from an estimated 17.72 under-five mortality per 1,000 lives in 2022 and 17.44 in 2021, according to the website of the UN Inter-agency Group for Child Mortality Estimation.
North Korea's under-five mortality rate surged to 107.68 per 1,000 live births in 1995 as the country fell into a severe famine following the dissolution of the Soviet Union.
The country had seen significant improvements since 2003, gradually reducing the rate to 17.7 in 2019 and 17.45 in 2020, reaching a low of 17.44 in 2021.
The website did not provide clear reasons for the increases from 2021 to 2023, but they may be related to the country's pandemic-era border controls, which affected inoculation rates among North Korean children.
According to UNICEF, only 41 percent of children in North Korea received the first dose of the diphtheria-tetanus-pertussis vaccine in 2023.
In 2023, the UN-estimated infant mortality rate in North Korea reached 14.54 per 1,000 births, while the neonatal mortality rate stood at 9.63.
The same year, the estimated under-five mortality rate in South Korea stood at 2.76 per 1,000 live births. (Yonhap)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
6 hours ago
- Korea Herald
Health minister nominee Jung Eun-kyeong, disease specialist who spearheaded battle against COVID-19
Jung Eun-kyeong, President Lee Jae-myung's pick to head the Ministry of Health and Welfare, earned nationwide fame during her tenure as the inaugural commissioner of the Korea Disease Control and Prevention Agency. The 60-year-old was at the forefront of the nation's response to the COVID-19 pandemic, and headed the KDCA as a vice minister-level official from September of 2020 to May 2022. She joined Lee's presidential campaign this year, ahead of the June 3 presidential election. She had risen through the ranks of the KDCA's forerunner National Institute of Health since joining in 1955, then through the KDCA as an expert in disease control. If her appointment to the minister post is confirmed, it would be the first time since 2017 that a medical doctor would be heading the Health Ministry. One of her tasks as the new Health Minister would be to resolve the ongoing confrontation between the government and the medical circles, which has been going on since February of last year when trainee doctors across the country engaged in a mass walkout.
Korea Herald
2 days ago
- Korea Herald
Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies
SEOUL, South Korea, June 27, 2025 /PRNewswire/ -- As respiratory illnesses like COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the need for safe, non-pharmaceutical prevention options is growing. South Korea–based biotech firm LUCA AICELL has developed LUCA V-Defense Nasal Spray, a drug-free nasal spray designed to form a protective barrier on the nasal lining—offering a modern solution in the post-mask era. A Physical Barrier, Not a Medication Unlike traditional nasal sprays that rely on steroids or antihistamines, LUCA V-Defense forms a non-medicated barrier across the nasal mucosa, the body's first line of defense against airborne pathogens. Instead of using steroids, antihistamines, or vasoconstrictors, LUCA V-Defense relies on lambda carrageenan, a natural compound extracted from red algae, and antimicrobial lipids. These ingredients coat the nasal lining, helping to prevent viruses like SARS-CoV-2 and influenza from binding to mucosal cells. Recent studies have also shown that lambda carrageenan not only possesses antiviral properties but also exhibits anti-inflammatory and anti-allergic effects, helping to reduce allergic reactions in nasal tissues and inhibit histamine release, which may contribute to the prevention of allergic rhinitis. Using LUCA's proprietary lipid nanocoating technology, the nasal spray demonstrated 99.7% antiviral efficacy within one minute in an in vitro third-party COVID-19 lab study overseas. This suggests potential across a broad spectrum of respiratory viruses. Rapid Adoption and International Certifications LUCA AICELL reports that sales of LUCA V-Defense more than tripled in the most recent quarter, signaling increasing consumer interest in preventive nasal sprays. This demand is especially strong among parents and travelers, given that no vaccine currently exists for Mycoplasma pneumonia, a common threat to children. LUCA V-Defense is classified as a medical device, not a pharmaceutical. It holds: These credentials validate its safety for daily use and its alignment with international regulatory standards. Safer than Steroid and Decongestant Sprays Many popular nasal congestion sprays contain steroids or vasoconstrictors like methazoline, which can offer fast symptom relief but are linked to rebound congestion, mucosal thinning, and reduced efficacy with long-term use. LUCA V-Defense addresses these issues with a plant-based, non-pharmaceutical formulation that's free from steroids, antihistamines, and methazoline. It is gentle enough for children, pregnant women, and individuals who suffer from seasonal allergies or chronic rhinitis. Its ease of use, a simple mist inside each nostril, makes it ideal for travel, commutes, or high-exposure environments like offices, schools, or public transit. As the world transitions away from masks and into a new phase of pandemic management, personal preventive tools like LUCA V-Defense are gaining relevance. Whether navigating crowded airports, allergy season, or cold and flu outbreaks, this daily-use nasal spray offers a chemical-free alternative for respiratory defense. "The pandemic changed how we think about personal protection," said a LUCA AICELL spokesperson. "LUCA V-Defense was developed not just for short-term response, but for long-term respiratory wellness. We see it as a smart, science-backed addition to modern health routines."
Korea Herald
3 days ago
- Korea Herald
Infectious disease cases up 54.5% in South Korea
South Korea saw a 54.5 percent rise in non-COVID notifiable infectious disease cases in 2024 compared to the previous year, driven largely by a surge in respiratory illnesses among children, according to a new report from the Korea Disease Control and Prevention Agency on Thursday. The 2024 annual report on infectious disease, based on data from the newly launched integrated control information system, found that 168,586 cases of first to third-tier notifiable diseases — excluding COVID-19 and syphilis, which both had changes in their tiers — were reported last year, up from 109,087 in 2023. Pertussis, otherwise known as whooping cough, accounted for much of the increase, with cases jumping from just 292 in 2023 to 48,048, over a 164-fold increase, in 2024. Scarlet fever and chickenpox also surged, with 6,642 and 31,892 cases reported, respectively. Carbapenem-resistant Enterobacteriaceae, a dangerous antibiotic-resistant infection, reached 42,347 cases. Despite the overall increase in these illnesses, the total number of reported cases of all monitored infectious diseases plummeted by 97 percent from 2023, largely due to the reclassification of COVID-19 as a lower-tier disease. The number of deaths from notifiable diseases, excluding tuberculosis, rose 18.2 percent to 1,238 in 2024. CRE infections were the leading cause of death among these, with 838 fatalities. KDCA Commissioner Jee Young-mee emphasized the importance of early reporting by medical institutions. "Reporting infectious disease is the first line of defense to minimize the damage from the spread of diseases, by detecting them at an early stage and stop its transmission to the community," she said.
